Alps Advisors Inc. Takes $335,000 Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Alps Advisors Inc. purchased a new stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,535 shares of the specialty pharmaceutical company’s stock, valued at approximately $335,000. Alps Advisors Inc. owned about 0.06% of Eagle Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EGRX. US Bancorp DE grew its position in shares of Eagle Pharmaceuticals by 52.3% in the second quarter. US Bancorp DE now owns 879 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 302 shares during the last quarter. KBC Group NV acquired a new stake in Eagle Pharmaceuticals during the second quarter worth approximately $41,000. Lazard Asset Management LLC boosted its position in Eagle Pharmaceuticals by 80.1% during the second quarter. Lazard Asset Management LLC now owns 4,330 shares of the specialty pharmaceutical company’s stock worth $192,000 after acquiring an additional 1,926 shares during the last quarter. Everence Capital Management Inc. acquired a new stake in Eagle Pharmaceuticals during the second quarter worth approximately $221,000. Finally, OLD Mission Capital LLC acquired a new stake in Eagle Pharmaceuticals during the second quarter worth approximately $226,000. 88.49% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ EGRX opened at $37.32 on Wednesday. Eagle Pharmaceuticals, Inc. has a 1 year low of $24.35 and a 1 year high of $56.43. The firm’s 50 day moving average price is $30.81 and its 200 day moving average price is $37.65. The firm has a market cap of $485.76 million, a P/E ratio of 19.44 and a beta of 0.80. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.99 and a current ratio of 1.52.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 11th.

Insiders Place Their Bets

In other Eagle Pharmaceuticals news, Director Richard A. Edlin sold 6,800 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $30.99, for a total transaction of $210,732.00. Following the transaction, the director now owns 22,600 shares of the company’s stock, valued at $700,374. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 28.20% of the stock is currently owned by insiders.

Eagle Pharmaceuticals Company Profile

(Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Featured Stories

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.